LRMR (Larimar Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by LRMR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-08 | Thomas Edward Hamilton | Director | Buy | — | — |
| 2026-05-20 | JEFFREY W SHERMAN | Director | A | — | — |
| 2026-05-20 | Thomas Edward Hamilton | Director | A | — | — |
| 2026-05-20 | JONATHAN S LEFF | Director | A | — | — |
| 2026-05-20 | Joseph Truitt | Director | A | — | — |
| 2026-05-20 | DEERFIELD MANAGEMENT COMPANY, L.P. | Director | A | — | — |
| 2026-05-20 | FRANK E THOMAS | Director | A | — | — |
| 2026-03-02 | FRANK E THOMAS | Director | Buy | — | — |
| 2026-03-02 | JEFFREY W SHERMAN | Director | Buy | — | — |
| 2026-03-02 | Thomas Edward Hamilton | Director | Buy | — | — |
| 2026-03-02 | Deerfield Mgmt III, L.P. | Director | Buy | — | — |
| 2026-01-27 | Gopi Shankar | Chief Development Officer | A | — | — |
| 2026-01-27 | CAROLE BEN-MAIMON | President and CEO | A | — | — |
| 2026-01-27 | Russell Clayton | Chief Medical Officer | A | — | — |
| 2026-01-27 | Michael Celano | Chief Financial Officer | A | — | — |
| 2025-08-04 | DEERFIELD PARTNERS, L.P. | Director | Buy | — | — |
| 2025-05-15 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | Director | A | — | — |
| 2025-05-14 | FRANK E THOMAS | Director | A | — | — |
| 2025-05-14 | Joseph Truitt | Director | A | — | — |
| 2025-05-14 | JEFFREY W SHERMAN | Director | A | — | — |
| 2025-05-14 | JONATHAN S LEFF | Director | A | — | — |
| 2025-05-14 | Thomas Edward Hamilton | Director | A | — | — |
| 2025-01-24 | Russell Clayton | Chief Medical Officer | A | — | — |
| 2025-01-24 | Gopi Shankar | Chief Development Officer | A | — | — |
| 2025-01-24 | CAROLE BEN-MAIMON | President and CEO | A | — | — |
| 2025-01-24 | Michael Celano | Chief Financial Officer | A | — | — |
| 2024-06-03 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | Director | A | — | — |
| 2024-05-31 | FRANK E THOMAS | Director | A | — | — |
| 2024-05-31 | JEFFREY W SHERMAN | Director | A | — | — |
| 2024-05-31 | Thomas Edward Hamilton | Director | Buy | — | — |
| 2024-05-31 | JONATHAN S LEFF | Director | A | — | — |
| 2024-05-31 | Joseph Truitt | Director | A | — | — |
| 2024-02-16 | Deerfield Mgmt IV, L.P. | Director | Buy | — | — |
| 2024-02-15 | FRANK E THOMAS | Director | Buy | — | — |
| 2024-01-19 | Russell Clayton | Chief Medical Officer | A | — | — |
| 2024-01-19 | Michael Celano | Chief Financial Officer | A | — | — |
| 2024-01-19 | Gopi Shankar | Chief Development Officer | A | — | — |
| 2024-01-19 | CAROLE BEN-MAIMON | President and CEO | A | — | — |
| 2023-12-08 | Gopi Shankar | Chief Development Officer | Buy | — | — |
| 2023-10-05 | JEFFREY W SHERMAN | Director | A | — | — |
| 2023-07-18 | Russell Clayton | Chief Medical Officer | A | — | — |
| 2023-05-18 | CAROLE BEN-MAIMON | President and CEO | Buy | — | — |
| 2023-05-18 | Michael Celano | Chief Financial Officer | Buy | — | — |
| 2023-05-18 | Joseph Truitt | Director | Buy | — | — |
| 2023-05-11 | Joseph Truitt | Director | A | — | — |
| 2023-05-11 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | Director | A | — | — |
| 2023-05-11 | FRANK E THOMAS | Director | A | — | — |
| 2023-05-11 | JONATHAN S LEFF | Director | A | — | — |
| 2023-05-11 | Thomas Edward Hamilton | Director | A | — | — |
| 2023-02-09 | Gopi Shankar | Chief Development Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 9,538,945 | — |
| — | Director | 6,207,982 | — |
| — | Director | 4,721,197 | — |
| — | Director | 4,721,183 | — |
| — | Director | 1,943,423 | — |
| — | Director | 874,231 | — |
| — | President and CEO | 399,432 | — |
| — | Chief Financial Officer | 215,785 | — |
| — | Chief Development Officer | 76,443 | — |
| — | Chief Medical Officer | 71,443 | — |
| — | Director | 7,000 | — |
| — | Director | 5,000 | — |
| — | Director | 2,750 | — |
| — | 10%+ Owner | 8 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the LRMR quote page; the site-wide leaderboard is on the insider transactions hub.